Acasă › Leucemie limfoblastică acută › Washington › Seattle
Studii clinice pentru Leucemie limfoblastică acută în Seattle, WA
21 studii pentru Leucemie limfoblastică acută caută participanți în și în jurul orașului Seattle (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
În curs de recrutare
- Seattle Children's, University of Washington, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- și încă 1
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Center, Seattle
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
În curs de recrutareFaza 2
- Seattle Children's Hospital, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
În curs de recrutareFaza 1/2
- Seattle Children's Hospital, Seattle
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
În curs de recrutareStudiu observațional
- Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Seattle
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
În curs de recrutareFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
În curs de recrutareFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Multicenter HomeVENT: Home Values and Experiences Navigation Track
În curs de recrutareVoluntari sănătoși bineveniți
- Seattle Childrens Hospital, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
În curs de recrutareStudiu observațional
- Fred Hutchinson Cancer Research Center, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
În curs de recrutareFaza 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
În curs de recrutareFaza 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
În curs de recrutareFaza 2Voluntari sănătoși bineveniți
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
În curs de recrutareFaza 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
În curs de recrutareStudiu observațional
- Seattle Children's Hospital, Seattle
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
În curs de recrutareFaza 3
- Ascentage Investigative Site #1806, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
În curs de recrutareFaza 2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
În curs de recrutareFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Research Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Center, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
În curs de recrutareFaza 1
- Seattle Children's Hospital, Seattle
Studii pentru Leucemie limfoblastică acută în alte orașe
- Houston, TX28 studii
- New York City, NY24 studii
- Baldwin Park, CA21 studii
- Chicago, IL19 studii
- Atlanta, GA19 studii
- Philadelphia, PA16 studii
- Memphis, TN16 studii
- Washington, DC16 studii
- Boston, MA15 studii
- Los Angeles, CA14 studii
- Durham, NC13 studii
- Mountain View, CA13 studii
Alte studii în Seattle
- Cancer pulmonar cu celule non-pătrate53 studii
- Cancer (toate tipurile)49 studii
- Cancer de prostată42 studii
- Leucemie mieloasă acută40 studii
- Cancer de sân39 studii
- Cancer metastatic39 studii
- Cancer colorectal34 studii
- Cancer pulmonar33 studii
- Cancer ovarian30 studii
- Mielom multiplu22 studii
- Sindroame mielodisplastice21 studii
- Cancer de vezică urinară21 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.